Merck (MRK) Dividend Coverage Ratio (2009 - 2026)
Merck's (MRK) quarterly Dividend Coverage Ratio came in at 0.62 in Q2 2026, down 129.25% year-over-year from 2.13 in Q2 2025, and up 69.06% quarter-over-quarter from 2.02 in Q1 2026.
Analysis
Merck (MRK) Dividend Coverage Ratio (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Dividend Coverage Ratio for 18 consecutive years, with 0.62 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Dividend Coverage Ratio fell 129.25% year-over-year to 0.62 in Q2 2026; TTM through Jun 2026 was 0.38, a 81.32% decrease from a year earlier, with the FY2025 full-year figure at 2.23, up 2.21% from the prior year.
- Dividend Coverage Ratio was 0.62 for Q2 2026 at Merck, up from 2.02 in the prior quarter.
- Over five years, Dividend Coverage Ratio peaked at 2.85 in Q3 2025 and troughed at 3.17 in Q2 2023.
- A 5-year average of 1.31 and a median of 1.89 in 2022 frame the typical range for Dividend Coverage Ratio.
- Across the five-year window, Dividend Coverage Ratio slumped 242.0% in 2023 and soared 389.89% in 2024, its largest moves.
- Over 5 years, Dividend Coverage Ratio stood at 1.72 in 2022, then slumped by 138.39% to 0.66 in 2023, then soared by 389.89% to 1.92 in 2024, then slipped by 23.51% to 1.47 in 2025, then sank by 142.49% to 0.62 in 2026.
- The last three Dividend Coverage Ratio figures came in at 0.62 (Q2 2026), 2.02 (Q1 2026), and 1.47 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.28 Bn | 626.53 Bn | 17.26 Bn | 1.71 |
| 2 | AbbVie | 442.02 Bn | 435.45 Bn | 12.70 Bn | 1.18 |
| 3 | Merck | 364.57 Bn | 357.43 Bn | 12.21 Bn | -0.62 |
| 4 | Novartis Ag | 267.21 Bn | 259.52 Bn | 11.24 Bn | 1.14 |
| 5 | Pfizer | 158.97 Bn | 147.27 Bn | 10.94 Bn | -0.10 |
| 6 | Sanofi | 52.50 Bn | 45.12 Bn | 10.79 Bn | 0.07 |
| 7 | Revolution Medicines | 44.22 Bn | 44.22 Bn | - | - |
| 8 | Incyte | 25.43 Bn | 20.89 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.38 Bn | 18.72 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.62 |
| Mar 31, 2026 | -2.02 |
| Dec 31, 2025 | 1.47 |
| Sep 30, 2025 | 2.85 |
| Jun 30, 2025 | 2.13 |
| Mar 31, 2025 | 2.48 |
| Dec 31, 2024 | 1.92 |
| Sep 30, 2024 | 1.62 |
| Jun 30, 2024 | 2.75 |
| Mar 31, 2024 | 2.44 |
| Dec 31, 2023 | -0.66 |
| Sep 30, 2023 | 2.56 |
| Jun 30, 2023 | -3.17 |
| Mar 31, 2023 | 1.52 |
| Dec 31, 2022 | 1.72 |
| Sep 30, 2022 | 1.86 |
| Jun 30, 2022 | 2.23 |
| Mar 31, 2022 | 2.47 |
| Dec 31, 2021 | 2.29 |
| Sep 30, 2021 | 2.77 |